Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MCARH109 |
Synonyms | |
Therapy Description |
MCARH109 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting GPRC5D and CD137 (4-1BB), which may selective recognize GPRC5D expressing tumor cells and activate anti-tumor immune response (PMID: 36170501). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MCARH109 | MCARH-109|MCARH 109 | MCARH109 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting GPRC5D and CD137 (4-1BB), which may selective recognize GPRC5D expressing tumor cells and activate anti-tumor immune response (PMID: 36170501). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04555551 | Phase I | MCARH109 | MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma | Active, not recruiting | USA | 0 |